Our division investigates the processes that drive normal blood cell development. We aim to identify the nature of defects that subvert these processes, causing the development of cancer.

Collaborations between our researchers, biotech and pharmaceutical companies have led to the development of drugs that have been approved or are currently being tested in clinical trials for the treatment of blood cancers and other diseases.

Building on this, we continue to focus our efforts on developing improved treatments for people with cancer and to make the basic research discoveries that will lead to future breakthrough cancer therapies.

Health impact

Cancers: brain cancer, leukaemia, lung cancer, lymphoma, myeloma, melanoma, myeloproliferative disorders 

Division news

• Team behind new cancer drug wins Clunies Ross Award
• Cancer mutation discovery could improve targeted leukaemia treatment
• Mutant protein tackles DNA guardian to promote cancer development
• New model mimics human tumours for accurate testing of cancer drugs
• New clues about how our body guards against cancer

Division head

Professor Andreas Strasser

Lab heads

Professor Jerry Adams

Professor Warren Alexander

Professor Suzanne Cory

Dr Nadia Davidson

Professor Doug Hilton

Professor David Huang

Associate Professor Gemma Kelly

Associate Professor Ruth Kluck

Associate Profesor Ian Majewski

Professor Nick Nicola

Professor Andrew Roberts

Professor Christine Wells (Honorary)

Division coordinators

Michelle Birrell